An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski, et al.·2008·The Lancet